BSEBoard Meeting29 Oct 2026 · 29 Oct 2026, 05:17 pm

Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026

Bliss GVS Pharma Ltd · 506197

✦ AI SummaryResults

Bliss GVS Pharma Ltd has announced the outcome of its board meeting, which was held on October 29, 2026, through video conferencing. The board has approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the limited review report of the auditors.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk3/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026

Attachments (1)

📄

b7722692-2218-437b-a74a-16dc759bd219.pdf

pdf

Download →
View document text
October 29, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Ltd. BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Subject: Outcome of Board Meeting held on Thursday, October 29, 2026 Dear Sir/Madam, We wish to inform you that the Board Meeting of the Company was held today i.e. on Thursday, October 29, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. A copy of the unaudited standalone and consolidated financial results, along with the Limited Review Report of the Auditors, is enclosed below. The Board of Directors meeting commenced at 2:30 p.m. and concluded at 4:00 p.m. Kindly take the above information on record and acknowledge it. Thanking you. Yours faithfully, For Bliss GVS Pharma Limited Deepak Sawant Chief Financial Officer Encl: As above